

1
2 UNITED STATES DISTRICT COURT
3 FOR THE DISTRICT OF NEW JERSEY

4 _____
5 HELSINN HEALTHCARE, S.A. and
6 ROCHE PALO ALTO, LLC,

7 Plaintiffs,

8 -vs-

9 DR. REDDY'S LABORATORIES, LTD.,
10 DR. REDDY'S LABORATORIES, INC.,
11 TEVA PHARMACEUTICALS USA, INC.,
12 and TEVA PHARMACEUTICAL
13 INDUSTRIES, LTD.

14 Defendants.

15 _____
16 Clarkson S. Fisher United States Courthouse
17 402 East State Street
18 Trenton, New Jersey 08608
19 June 8, 2015

20 **B E F O R E:**

21 THE HONORABLE MARY L. COOPER
22 UNITED STATES DISTRICT JUDGE

23 Certified as True and Correct as required by Title 28, U.S.C.,
24 Section 753

25 /S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR

/S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA

Dr. Reddy's Laboratories, Ltd., et al.

v.

Helsinn Healthcare S.A. et al

1 UNITED STATES DISTRICT COURT
2 FOR THE DISTRICT OF NEW JERSEY

3 _____
4 HELSINN HEALTHCARE, S.A. and
5 ROCHE PALO ALTO, LLC,

6 Plaintiffs,

7 -vs-

8 DR. REDDY'S LABORATORIES, LTD.,
9 DR. REDDY'S LABORATORIES, INC.,
10 TEVA PHARMACEUTICALS USA, INC.,
11 and TEVA PHARMACEUTICAL
12 INDUSTRIES, LTD.

13 Defendants.

14 _____
15 Clarkson S. Fisher United States Courthouse
16 402 East State Street
17 Trenton, New Jersey 08608
18 June 8, 2015

19 **B E F O R E:**

20 THE HONORABLE MARY L. COOPER
21 UNITED STATES DISTRICT JUDGE

22
23 Certified as True and Correct as required by Title 28, U.S.C.,
24 Section 753

25 /S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR

/S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

A P P E A R A N C E S:

PAUL HASTINGS

BY: JOSEPH O'MALLEY, ESQUIRE
ERIC W. DITTMANN, ESQUIRE
ISAAC S. ASHKENAZI, ESQUIRE

SAUL EWING

BY: CHARLES M. LIZZA, ESQUIRE
Attorneys for the Plaintiffs

BUDD LARNER

BY: STUART D. SENDER, ESQUIRE
MICHAEL H. IMBACUAN, ESQUIRE
HUA HOWARD WANG, ESQUIRE
CONSTANCE S. HUTTNER, ESQUIRE
KENNETH E. CROWELL, ESQUIRE

Attorneys for the Defendant, Dr. Reddy's Laboratories

WINSTON & STRAWN

BY: JOVIAL WONG, ESQUIRE
GEORGE LOMBARDI, ESQUIRE
JULIA MANO JOHNSON, ESQUIRE
BRENDAN F. BARKER, ESQUIRE
LITE DePALMA, GREENBERG, LLC
BY: MAYRA V. TARANTINO, ESQUIRE
Attorneys for the Defendant, Teva

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25

I N D E X

WITNESS VOIR DIRECT CROSS REDIRECT RECROSS
 DIRE

David G. Frame
By Mr. Imbacuan
By Mr. Ashkenazi

1 BY MR. IMBACUAN:

2 Q. Dr. Frame, Chelly is also a study concerning the use of
3 palonosetron for PONV. So how do the findings relate to the
4 use of palonosetron for CINV?

5 A. Right. So you can't make an absolute direct correlation
6 because PONV and CINV, as I explained earlier, are different
7 entities. Okay?

8 Now, historically, we had studies with ondansetron,
9 dolasetron and granisetron in both PONV and CINV, PONV and
10 CINV. And, in general, it usually was about 2- to 10-fold
11 higher dose for CINV than it was for PONV. But you really
12 have to do the trials in CINV to get the absolute dose because
13 it's a fairly broad range.

14 But the more potent the drug was, the less conversion
15 that you actually needed because, again, the more potent that
16 drug is, it can -- it binds to those receptors really, really,
17 really strongly, right? Usually more potent has very high
18 affinity so they bind to the receptors very strongly. And so
19 the lower the dose that's usually required with the more
20 potent drug, it wasn't as big of a conversion.

21 THE COURT: Between --

22 THE WITNESS: Between --

23 THE COURT: -- CINV and PONV?

24 THE WITNESS: Correct.

25 THE COURT: Or vice versa?

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.